Skip to main content
Atrás
GMAB logo

Genmab A/S

Calidad de datos: 100%
GMAB
NASDAQ Healthcare Biotechnology
$25.81
▲ $0.13 (0.51%)
Cap. Mercado: 15.94B
También listada como GNMSF OTC
Rango del Día
$25.43 $25.86
Rango de 52 Semanas
$17.24 $35.43
Volumen
1,562,050
Promedio 50D / 200D
$30.31 / $27.96
Cierre Anterior
$25.68

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E 2.6 0.3
P/B 0.4 2.9
ROE % 16.6 3.7
Net Margin % 25.9 3.8
Rev Growth 5Y % 29.6 10.0
D/E 1.0 0.2

Precio Objetivo de Analistas

Hold
$40.50 +56.9%
Low: $34.00 High: $48.00
P/E Futuro
20.8
EPS Futuro
$1.24
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
4.3 B

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $2.68
$2.46 – $2.88
 6.5 B 4
FY2029 $2.42
$2.22 – $2.60
 6.2 B 4
FY2028 $2.61
$1.81 – $3.39
 6.1 B 10

Puntos Clave

Revenue grew 29.58% annually over 5 years — strong growth
Earnings declined -21.69% over the past year
ROE of 16.63% — decent returns on equity
Net margin of 25.89% shows strong profitability
Generating 7.33B in free cash flow
P/E of 2.59 — trading at a low valuation

Crecimiento

Revenue Growth (5Y)
29.58%
Revenue (1Y)10.23%
Earnings (1Y)-21.69%
FCF Growth (3Y)2.29%

Calidad

Return on Equity
16.63%
ROIC8.24%
Net Margin25.89%
Op. Margin33.60%

Seguridad

Debt / Equity
0.95
Current Ratio2.02
Interest Coverage20.49

Valoración

P/E Ratio
2.59
P/B Ratio0.43
EV/EBITDA5.07
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10.23% Revenue Growth (3Y) 20.01%
Earnings Growth (1Y) -21.69% Earnings Growth (3Y) 18.80%
Revenue Growth (5Y) 29.58% Earnings Growth (5Y) 20.05%
Profitability
Revenue (TTM) 23.73B Net Income (TTM) 6.14B
ROE 16.63% ROA 7.50%
Gross Margin 91.69% Operating Margin 33.60%
Net Margin 25.89% Free Cash Flow (TTM) 7.33B
ROIC 8.24% FCF Growth (3Y) 2.29%
Safety
Debt / Equity 0.95 Current Ratio 2.02
Interest Coverage 20.49 Dividend Yield 0.00%
Valuation
P/E Ratio 2.59 P/B Ratio 0.43
P/S Ratio 0.67 PEG Ratio -1.06
EV/EBITDA 5.07 Dividend Yield 0.00%
Market Cap 15.94B Enterprise Value 40.39B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 23.73B 21.53B 16.47B 14.51B 8.42B
Net Income 6.14B 7.84B 4.35B 5.45B 2.96B
EPS (Diluted) 9.79 12.14 6.60 8.26 4.48
Gross Profit 21.76B 20.54B 16.25B 14.51B 8.42B
Operating Income 7.97B 6.70B 5.32B 6.27B 2.95B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 81.86B 45.81B 35.29B 30.12B 24.63B
Total Liabilities 44.68B 9.11B 3.68B 2.84B 2.43B
Shareholders' Equity 37.18B 36.70B 31.61B 27.28B 22.20B
Total Debt 35.36B 1.03B 770.00M 597.00M 425.00M
Cash & Equivalents 10.91B 9.86B 14.87B 9.89B 8.96B
Current Assets 18.35B 27.85B 33.14B 28.22B 22.74B
Current Liabilities 9.07B 5.31B 2.48B 1.82B 1.57B

Puntuaciones de Estrategias

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#160 of 1052
65
Custom Capital Light Compounder
#139 of 218
34
Growth Price/Sales Ratio Focus (Ken Fisher)
#213 of 618
46
Custom Contrarian Investing (David Dreman)
#388 of 670
24

Actividad Reciente

Entró Cash Flow Compounder
Mar 24, 2026
Entró Capital Light Compounder
Mar 24, 2026
Entró Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entró Contrarian Investing (David Dreman)
Mar 24, 2026